• Stimulates healing due to its tissue engineered structure, which includes an outer layer of living keratinocytes and stem cells and an inner layer of living fibroblasts contained within a collagen matrix
• Mechanism of action clinical study demonstrated that living keratinocytes and fibroblasts produce potent healing signals to convert the wound from a chronic to an acute state
• Proven to heal more venous leg ulcers and diabetic foot ulcers faster in randomized controlled trials and in real-world observational studies

Apligraf® is indicated for use with standard therapeutic compression for the treatment of non-infected partial- and full-thickness skin ulcers due to venous insufficiency of greater than one month duration and which have not adequately responded to conventional ulcer therapy.

Apligraf® is also indicated for use with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than three weeks duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.

Apligraf® is contraindicated for use on clinically infected wounds. Contraindicated in patients with known allergies to bovine collagen or with a known hypersensitivity to the components of the Apligraf® agarose shipping medium.

If the expiration date or product pH (6.8-7.7) is not within the acceptable range DO NOT OPEN AND DO NOT USE the product. A clinical determination of wound infection should be made based on all of the signs and symptoms of infection. Please refer to the Apligraf® package insert for additional information.

All reported adverse events, which occurred at an incidence of greater than 1% in the clinical studies, are listed in Table 1, Table 2 and Table 3 in the full package insert. These tables list adverse events both attributed and not attributed to treatment. Please refer to the Apligraf® package insert for additional information.

Apligraf® has been processed under aseptic conditions and should be handled observing sterile technique. It should be kept in its tray on the medium in the sealed bag under controlled temperature 68°F-73°F (20°C-23°C) until ready for use. Please refer to the Apligraf® package insert for additional information.